Thomas Lee, Fundstrat Global Advisors Managing Partner & Head of Research, discusses the search for yield and gives his top picks.
CVS Health's new "excluded" list includes medications used in treatment of patients with cancer, diabetes and hepatitis C.
CNBC's Meg Tirrell reports the latest of what Pfizer CEO Ian Read has to say on biotech valuations, the election and more. The “Fast Money Halftime Report” traders and Stephanie Link, TIAA Global Asset Management, weigh in.
John Lechleiter, Eli Lilly CEO, and David Ricks, incoming Eli Lilly CEO, dicusses the need to make changes around the Affordable Care Act.
John Lechleiter, Eli Lilly CEO, and David Ricks, incoming Eli Lilly CEO talk about Eli Lilly's succession plan as the company launches a new chapter in its history.
Eli Lilly on Monday announced that John Lechleiter, its chairman, president and CEO, will retire from the company effective December 31, 2016.
Eli Lilly reports better-than-expected quarterly sales, driven by demand for its newer treatments for diabetes and cancer.
Some of the names on the move ahead of the open.
John Lechleiter, Eli Lily CEO, breaks down the company's quarterly results which reported EPS of $0.86 Adj on revenues of $5.40 billion. Also Lechleiter provides an update on new drug approvals and weighs in on drug pricing.
CNBC's Meg Tirrell reports on the health of the biotech sector and what could spur a turnaround in the second half of the year.
Amgen said Wednesday that it has seen positive results for the chronic-migraine prevention drug it has been developing with Novartis.
Facebook was the top buy for hedge funds in the first quarter; Apple was the top sell.
Eli Lilly CEO John Lechleiter talks about the impact of the dollar, taxes, and the problem he sees with the Trans-Pacific Partnership agreement. Also Lechleiter provides an update on Alzheimer's treatment.
Eli Lilly CEO John Lechleiter discusses cycles in the industry and products coming out of the company's labs. We're very optimistic about our future, says Lechleiter. We have a chance to introduce 20 new products in the next ten years and are off to a good running start.
Ringing today's opening bell are Eli Lilly and Company CEO John Lechleiter, at the NYSE, and USO of Metropolitan New York Brian Whiting, at the Nasdaq.
Today's bell ringers are Eli Lilly and Company CEO John Lechleiter, at the NYSE, and USO of Metropolitan New York Brian Whiting, at the Nasdaq.
The Credit Suisse research team presented their highest conviction stock ideas in a note to clients Wednesday.
The FMHR traders and Stephanie Link of TIAA Global Asset Management, take their positions on stocks in earnings news, including Procter & Gamble's turnaround story.
Eli Lilly reports lower-than-expected earnings due largely to heavy spending on research.
U.S. stock-index futures traded higher, amid a busy day for earnings and the start of a Federal Reserve policy meeting.